Back to Search
Start Over
Trends in chemotherapy use for early-stage breast cancer from 2006 to 2019
- Source :
- Breast Cancer Research, Vol 26, Iss 1, Pp 1-7 (2024)
- Publication Year :
- 2024
- Publisher :
- BMC, 2024.
-
Abstract
- Abstract Background Little is known about how use of chemotherapy has evolved in breast cancer patients. We therefore describe chemotherapy patterns for women with stage I-IIIA breast cancer in the Optimal Breast Cancer Chemotherapy Dosing (OBCD) Study using data from KPNC (Kaiser Permanente Northern California) and KPWA (Kaiser Permanente Washington). Findings Among 33,670 women, aged 18 + y, diagnosed with primary stage I-IIIA breast cancer at KPNC and KPWA from 2006 to 2019, we explored patterns of intravenous chemotherapy use, defined here as receipt of intravenous cytotoxic drugs and/or anti-HER2 therapies. We evaluated trends in chemotherapy receipt, duration over which chemotherapy was received, and number of associated infusion visits. In secondary analyses, we stratified by receipt of anti-HER2 therapies (trastuzumab and/or pertuzumab), given their longer duration. 38.9% received chemotherapy intravenously, declining from 40.2% in 2006 to 35.6% in 2019 (p-trend
Details
- Language :
- English
- ISSN :
- 1465542X
- Volume :
- 26
- Issue :
- 1
- Database :
- Directory of Open Access Journals
- Journal :
- Breast Cancer Research
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.4df8f5cdae74a1a8836527359a19293
- Document Type :
- article
- Full Text :
- https://doi.org/10.1186/s13058-024-01822-9